Original Research Article (Pfizer): First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article
Original Research Article: Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was
POSTER: Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation (Poster No. 433 #AACR2021 in partnership with Leap Therapeutics)
Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study,
POSTER: Characterizing the Heterogeneity of CD8 Inflammation in Biopsied Tumor Tissues Using Novel Image Analysis Techniques (Poster No. 3137 #AACR2021 in partnership with Scholar Rock)
Abstract One of the most studied immune cells in IO is the cytotoxic CD8 T cell, whose biological function is to identify and destroy infected
POSTER: A Novel Image Analysis Assay for Determining Programmed Death-Ligand (PD-L1 [22C3]) in Non-small Cell Lung Cancer that Accounts for Tissue and Alveolar Macrophages (Poster No. 435 #AACR2021)
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to
POSTER: Impact of adding Viagenpumatucel-L (HS-110) to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with Low Levels of Tumor Infiltrating Lymphocytes
Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology
